SCHEMBL4259731

SCHEMBL4259731

COC(=O)c1ccc(C=CCNCc2cccnc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.52
KMT2A Q03164 2/20 0.48
GAA P10253 2/20 0.48
ALDH1A1 P00352 6/20 0.48
POLB P06746 3/20 0.47
NAMPT P43490 1/20 0.47
NPSR1 Q6W5P4 2/20 0.46
USP2 O75604 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
CYP1A2 P05177 2/20 0.46
CYP2D6 P10635 1/20 0.46
KDM4E B2RXH2 2/20 0.45
HPGD P15428 2/20 0.45
TSHR P16473 2/20 0.45
HSD17B10 Q99714 1/20 0.45
HTT P42858 1/20 0.45
CYP3A4 P08684 1/20 0.44
BLM P54132 1/20 0.44
LMNA P02545 1/20 0.44
MAPK1 P28482 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4259730 1.00 THRB (0.52) THRBKMT2AGAAALDH1A1POLB
SCHEMBL20921263 0.85 RAB9A (0.58) KMT2AGAAALDH1A1L3MBTL1HPGD
SCHEMBL4933047 0.82 ALDH1A1 (0.66) KMT2AGAAALDH1A1POLBNPSR1
SCHEMBL4258773 0.78 HDAC1 (0.72) NAMPTCYP3A4
SCHEMBL4258770 0.78 HDAC1 (0.72) NAMPTCYP3A4
SCHEMBL8996089 0.77 ALDH1A1 (0.61) KMT2AALDH1A1CYP1A2CYP2D6KDM4E
SCHEMBL8996085 0.77 ALDH1A1 (0.61) KMT2AALDH1A1CYP1A2CYP2D6KDM4E
SCHEMBL8996130 0.77 ALDH1A1 (0.61) KMT2AALDH1A1CYP1A2CYP2D6KDM4E
SCHEMBL5158923 0.77 HDAC1 (0.60) KMT2AALDH1A1NAMPTHTTCYP3A4
SCHEMBL6727719 0.76 CA1 (0.69) KMT2AGAAALDH1A1POLBNAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090023734-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2009-01-22 US disclosed
US-7282608-B2 Inhibitors of histone deacetylase METHYLGENE, INC. (CA) 2007-10-16 US disclosed
US-20060020131-A1 Aryl amide, -sulfonamide, or -urea derivatives; antiproliferative, antitumor, anticarcinogenic, and/or antimetastasis agents METHYLGENE, INC. (CA) 2006-01-26 US disclosed
EP-1551795-A1 INHIBITORS OF HISTONE DEACETYLASE Methylgene, Inc. (CA) 2005-07-13 EP disclosed
WO-2004035525-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2004-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023734-A1 INHIBITORS OF HISTONE DEACETYLASE HDAC1, HDAC11, HDAC6 THRB 4093/4885KMT2A 76/4885GAA 106/4885
US-20060020131-A1 Aryl amide, -sulfonamide, or -urea derivatives; antiproliferative, antitumor, anticarcinogenic, and/or antimetastasis agents HDAC1, AADAC, HDAC11 THRB 3360/4885KMT2A 140/4885GAA 158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.